×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLRX – salarius pharmaceuticals, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/7
08:45 am
slrx
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
High
Report
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/8
12:38 pm
slrx
Form 8-K Salarius Pharmaceuticals For: Jan 08
Neutral
Report
Form 8-K Salarius Pharmaceuticals For: Jan 08
1/2
05:15 pm
slrx
Form 8-K Salarius Pharmaceuticals For: Dec 31
High
Report
Form 8-K Salarius Pharmaceuticals For: Dec 31
1/2
05:14 pm
slrx
Form 4 Salarius Pharmaceuticals For: Dec 30 Filed by: HANISH ARNOLD C
High
Report
Form 4 Salarius Pharmaceuticals For: Dec 30 Filed by: HANISH ARNOLD C
1/2
05:13 pm
slrx
Form 8-K Salarius Pharmaceuticals For: Dec 31
High
Report
Form 8-K Salarius Pharmaceuticals For: Dec 31
12/29
04:26 pm
slrx
Form PRE 14A Salarius Pharmaceuticals For: Feb 24
Low
Report
Form PRE 14A Salarius Pharmaceuticals For: Feb 24
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/27
Salarius Pharmaceuticals (NASDAQ: SLRX) is now covered by analysts at LADENBURG THALM/SH SH. They set a "buy" rating on the stock.
25.4%
8/26 Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma 21.4%
1/29 Form FWP Salarius Pharmaceuticals Filed by: Salarius Pharmaceuticals, Inc. 20.1%
12/16 Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma 13.4%
3/4 Salarius Announces Allowance of New European Patent Covering Seclidemstat 9.2%
3/25 Form 4 Salarius Pharmaceuticals For: Mar 23 Filed by: McCreedy Bruce J Jr. 7.9%
3/2 Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference 7.8%
2/18 Form 4 Salarius Pharmaceuticals For: Feb 18 Filed by: Jordan Scott 6.6%
2/12 Form 8-K Salarius Pharmaceuticals For: Feb 07 4.7%
11/26 Form 4 Salarius Pharmaceuticals For: Nov 25 Filed by: HANISH ARNOLD C 3.6%
8/26 Ivy Brain Tumor Center and Salarius Pharmaceuticals Launch Collaborative Partnership to Develop New Cancer Treatment for Glioblastoma 21.4%
1/29 Form FWP Salarius Pharmaceuticals Filed by: Salarius Pharmaceuticals, Inc. 20.1%
12/16 Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma 13.4%
3/4 Salarius Announces Allowance of New European Patent Covering Seclidemstat 9.2%
3/25 Form 4 Salarius Pharmaceuticals For: Mar 23 Filed by: McCreedy Bruce J Jr. 7.9%
3/2 Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference 7.8%
2/18 Form 4 Salarius Pharmaceuticals For: Feb 18 Filed by: Jordan Scott 6.6%
2/12 Form 8-K Salarius Pharmaceuticals For: Feb 07 4.7%
11/26 Form 4 Salarius Pharmaceuticals For: Nov 25 Filed by: HANISH ARNOLD C 3.6%
TOP News Decliners
2/7
Form EFFECT Salarius Pharmaceuticals
-58.5%
1/10 Form S-1 Salarius Pharmaceuticals -16.9%
7/29 Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell -16.2%
9/16 Form 8-K Salarius Pharmaceuticals For: Sep 10 -13.6%
9/12 Form 4 Salarius Pharmaceuticals For: Sep 10 Filed by: McVicar William K. -10.8%
1/28 Form S-1/A Salarius Pharmaceuticals -10.6%
2/6 Form S-1/A Salarius Pharmaceuticals -10.4%
7/29 Form SC 13D Salarius Pharmaceuticals Filed by: Sharma Sunil -10.2%
12/17 Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression -9.2%
9/12 Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month -9.1%
1/10 Form S-1 Salarius Pharmaceuticals -16.9%
7/29 Salarius Pharmaceuticals to Ring the Nasdaq Stock Market Opening Bell -16.2%
9/16 Form 8-K Salarius Pharmaceuticals For: Sep 10 -13.6%
9/12 Form 4 Salarius Pharmaceuticals For: Sep 10 Filed by: McVicar William K. -10.8%
1/28 Form S-1/A Salarius Pharmaceuticals -10.6%
2/6 Form S-1/A Salarius Pharmaceuticals -10.4%
7/29 Form SC 13D Salarius Pharmaceuticals Filed by: Sharma Sunil -10.2%
12/17 Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression -9.2%
9/12 Salarius Pharmaceuticals Supports Childhood Cancer Awareness Month -9.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: